For context, this effect size sits between that of cholinesterase inhibitors in Alzheimer’s disease (SMD: 0.38, 95% CI: 0.28 to 41.1; I2=41.1%),43 and MCI (SMD: 0.06, 95% CI: −0.08 to 0.20; I2=76%).44 This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.